About AIGEN Sciences
AIGEN Sciences is a company based in Seoul (South Korea) founded in 2021. AIGEN Sciences has raised $8.81 million across 2 funding rounds from investors including Premier Partners, K2 Investment Partners and Medytox Venture. AIGEN Sciences offers products and services including AI Drug Discovery Platform. AIGEN Sciences operates in a competitive market with competitors including BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
- Headquarter Seoul, South Korea
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website aigensciences.com
- Legal Name (주)아이젠사이언스
- Date of Incorporation 10 Aug, 1977
- Jurisdiction Maharashtra, India
- Total Equity Funding$8.81M (USD)
in 2 rounds
- InvestorsPremier Partners
& 6 more
Associated legal entities of AIGEN Sciences
AIGEN Sciences operates through , (active). Its filings, financials, charges and directors are on the company page.
| Legal entity | Status | Incorporated | Registered in | Revenue | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| , CIN U99999MH1977PLC010754 | Active | 10 Aug 1977 | Nanded, Maharashtra | – | – | – | View details |
Products & Services of AIGEN Sciences
AIGEN Sciences offers a comprehensive portfolio of products and services, including AI Drug Discovery Platform.
AI tool for discovering high-potency drugs with minimal toxicity.
Funding Insights of AIGEN Sciences
AIGEN Sciences has successfully raised a total of $8.81M across 2 strategic funding rounds. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $8.81M
- Total Rounds 2
- First Round $8.81M
(Oct 2024)
- Investors Count 7
All 2 funding rounds of AIGEN Sciences with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2025 | – | Series A | β | β | |
| Oct 2024 | $8.81M | Series A | β | β |
7 investors in total: 7 institutional.
Investors in AIGEN Sciences
AIGEN Sciences has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Premier Partners, K2 Investment Partners and Medytox Venture.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Private equity & venture capital firm | – | premierpartners.co.kr | Seoul, South Korea | |
- | – | medytoxventure.com | - | |
PE firm investing in South Korea and the US | – | partnersi.co.kr | Seoul, South Korea | |
Scale Up Partners is engaged in supporting university startups for commercialization. | – | supartners-cg.com | Seoul, South Korea | |
- | – | hyosungventures.net | - | |
- | 1997 | k2investment.co.kr | Seoul, South Korea | |
Investment management services are provided by QUAD Investment Management. | – | quadim.com | Seoul, Korea |
Investor details for AIGEN Sciences
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of AIGEN Sciences
1 people are tracked at AIGEN Sciences (1 in leadership).
| Name | Role | Group |
|---|---|---|
Jaewoo Kang | CEO | Leadership |
Complete people profiles for AIGEN Sciences
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of AIGEN Sciences
3 dated milestones of AIGEN Sciences across 4 years, from founding to its latest funding, stage changes and deals.
- Founded AIGEN Sciences is founded.
- Funding First funding round of $8.8M.
- Funding Latest funding round, Series A,.
Competitors of AIGEN Sciences
AIGEN Sciences operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BridgeBio, Spark Therapeutics, Alnylam, ATAI and Insitro, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bridgebio.com | 2015 | Palo Alto, United States | $434.2M | – | Therapeutics for genetic diseases are developed through targeted interventions. | |
| sparktx.com | 2013 | Philadelphia, United States | $82.8M | 822 | Gene therapies for rare diseases including retinal dystrophies are developed. | |
| alnylam.com | 2002 | Cambridge, United States | $17M | 2,100 | RNA interference-based therapeutics are developed for multiple disorders. | |
| atai.life | 2018 | Munich, Germany | $386.67M | – | A biopharmaceutical company accelerating innovative mental health treatments. | |
| insitro.com | 2018 | San Francisco, United States | $643.21M | 257 | An AI-enabled platform is developed for infectious disease treatment. | |
| ultragenyx.com | 2010 | Novato, United States | $135.1M | 837 | Therapeutics for rare and ultra-rare metabolic diseases are developed. | |
| forgebiologics.com | 2020 | Columbus, United States | $250M | 118 | Gene therapies for rare diseases are developed to treat patients. | |
| chimerix.com | 2002 | Durham, United Kingdom | $95.23M | 72 | Antiviral oral therapeutics are developed for infectious diseases and cancers. | |
| cariboubio.com | 2011 | Berkeley, United States | $156.55M | 92 | Provider of cell therapies to treat cancer and hematologic conditions |
Detailed competitors of AIGEN Sciences
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of AIGEN Sciences
The website of AIGEN Sciences (aigensciences.com) receives about 2.4K visits a month.
- Monthly visits2.4K
▲ 58.6% vs previous month
Latest news on Aigen Sciences
Complete news archive for AIGEN Sciences
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to AIGEN Sciences
10 companies that operate in the same segment as AIGEN Sciences (Genomics & Gene Therapy Platforms), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Provider of genetic test solutions to study ancestry, genealogy, and inherited traits | 2006 | Sunnyvale, California, United States | USD 943.53 M | USD 189.9 M | 265 | |
Provider of DNA testing services to create a family tree and ancestor | 2003 | Yehud, Central District, Israel | USD 40 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Gene therapies for rare diseases including retinal dystrophies are developed. | 2013 | Philadelphia, Pennsylvania, United States | USD 82.8 M | USD 64.73 M | 822 | |
Therapeutics for genetic diseases are developed through targeted interventions. | 2015 | Palo Alto, California, United States | USD 434.2 M | USD 502.08 M | 730 | |
Provider of an online genealogy platform offering a host of services | 1996 | Lehi, Utah, United States | USD 146.2 M | – | – |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about AIGEN Sciences
AIGEN Sciences was founded in 2021 and raised its 1st funding round 3 years after it was founded.
AIGEN Sciences is headquartered in Seoul, South Korea.
Jaewoo Kang is the current CEO of AIGEN Sciences.
AIGEN Sciences is a funded company, having raised a total of $8.81M across 2 funding rounds to date. The company's 1st funding round was a Series A of $8.81M, raised on Oct 2024.
AIGEN Sciences was founded in 2021 in Seoul, South Korea, focusing on the biotechnology sector. A proprietary platform named AIGEN Discovery has been developed to support drug discovery processes. Features include drug targeting, data analysis, and optimization of novel compounds. The tool is utilized by researchers for advancing pharmaceutical development through AI-driven methods. Operations are centered in South Korea, with applications in global research contexts.
AIGEN Sciences's top competitors include Spark Therapeutics, BridgeBio and Forge Biologics.
AIGEN Sciences offers AI Drug Discovery Platform.
AIGEN Sciences has 7 investors. Key investors include Premier Partners, K2 Investment Partners, Medytox Venture, Partners Investment, and QUAD Investment Management.
AIGEN Sciences operates through ,.